

Bibliography

- [1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011;144:646–674.
- [2] Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70.
- [3] Allinen M, Beroukhi R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell* 2004;6:17–32.
- [4] Cho RW, Clarke MF. Recent advances in cancer stem cells. *Curr Opin Genet Dev* 2008; 18:48–53.
- [5] Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. *Eur J Cancer* 2010;46:1181–1188.
- [6] Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003; 3:401–410.
- [7] Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. *J Cell Biol* 2010;188:759–768.
- [8] Society AC. *Cancer Facts & Figures 2012*, 2012.
- [9] Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. *J Clin Oncol* 2011;29:1835–1843.
- [10] Freedman AS, Friedberg JW. Treatment of Burkitt leukemia/lymphoma in adults. In: *UpToDate*, Lister A, Park J, Connor RF, eds. Waltham, MA: UpToDate, 2012 .
- [11] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–247.

- [12] Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. *Nature* 2008;452:580–589.
- [13] Ben-Haim S, Ell P. ¹⁸F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. *J Nucl Med* 2009;50:88–99.
- [14] Cherry SR. Multimodality Imaging: Beyond PET/CT and SPECT/CT. *Semin Nucl Med* 2009;39:348–353.
- [15] Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y, Jain RK. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. *Biophys J* 2002;83:1650–1660.
- [16] Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. *Trends Pharmacol Sci* 2008;29:57–61.
- [17] Schluep T, Hwang J, Cheng J, et al. Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models. *Clin Cancer Res* 2006;12:1606–1614.
- [18] Chauhan VP, Lanning RM, Diop-Frimpong B, et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. *Biophys J* 2009;97:330–336.
- [19] Schluep T, Hwang J, Hildebrandt IJ, et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. *P Natl Acad Sci Usa* 2009;106:11394–11399.
- [20] Thurber GM, Weissleder R. Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. *Mol Imaging Biol* 2011;13:623–632.
- [21] Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. *Cancer Sci* 2011;102:1247–1252.
- [22] Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov* 2008;7:771–782.
- [23] Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. *Mol Pharmaceut* 2009;6:659–668.

- [24] Davis ME. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. *Adv Drug Deliv Rev* 2009;61:1189–1192.
- [25] Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. *Curr Opin Chem Biol* 2005;9:674–679.
- [26] Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. *Anti-Cancer Drug* 2005;16:691–707.
- [27] Singh P, Destito G, Schneemann A, Manchester M. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. *J Nanobiotechnology* 2006;4:2.
- [28] Johnson EE, Lum HD, Rakhmilevich AL, et al. Intratumoral Immunocytokine Treatment Results in Enhanced Antitumor Effects. *J Immunother* 2006;29:635
10.1097/01.cji.0000211343.73588.59.
- [29] Johnson EE, Lum HD, Rakhmilevich AL, et al. Intratumoral immunocytokine treatment results in enhanced antitumor effects. *Cancer Immunol Immunother* 2008;57:1891–1902.
- [30] Schluep T, Cheng J, Khin K, Davis M. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. *Cancer Chemoth Pharm* 2006;57:654–662.
- [31] Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. *P Natl Acad Sci Usa* 2010;107:1235–1240.
- [32] Leamon CP, Reddy JA. Folate-targeted chemotherapy. *Adv Drug Deliv Rev* 2004;56:1127–1141.
- [33] Reddy GR, Bhojani MS, McConville P, et al. Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors. *Clin Cancer Res* 2006;12:6677–6686.
- [34] Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. *Science* 1980;210:1253–1255.

- [35] Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. *P Natl Acad Sci Usa* 2010;.
- [36] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* 2002;2:48–58.
- [37] Wong JYC, Chu DZ, Williams LE, et al. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. *Cancer Biol Ther* 2006;21:88–100.
- [38] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. *Nat Rev Clin Oncol* 2010;7:653–664.
- [39] Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *J Clin Oncol* 2001;19:3312–3322.
- [40] Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *P Natl Acad Sci Usa* 1998;95:4607–4612.
- [41] Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. *Nature* 2004;427:695.
- [42] Thorne RG, Lakkaraju A, Rodriguez-Boulan E, Nicholson C. In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. *P Natl Acad Sci Usa* 2008;105:8416–8421.
- [43] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. *Science* 2005;307:58–62.
- [44] Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. *Cancer Res* 1999;59:4129–4135.

- [45] Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D. Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. *Cancer Gene Ther* 2010;17:244–255.
- [46] McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. *Cancer Res* 2006;66:2509–2513.
- [47] Jarver P, Mager I, Langel U. In vivo biodistribution and efficacy of peptide mediated delivery. *Trends Pharmacol Sci* 2010;31:528–535.
- [48] Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. *Cancer Cell* 2009;16:510–520.
- [49] Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. *Science* 2010;328:1031–1035.
- [50] Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. *P Natl Acad Sci Usa* 2009;106:16157–16162.
- [51] Phelps ME. *PET : molecular imaging and its biological applications*. New York: Springer, 2004.
- [52] Cherry SR, Sorenson JA, Phelps ME. *Physics in nuclear medicine*. 3rd ed. Philadelphia, PA: Saunders, 2003.
- [53] Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. *J Nucl Med* 2008;49:64S–80.
- [54] Buerkle A, Weber WA. Imaging of tumor glucose utilization with positron emission tomography. *Cancer Metast Rev* 2008;27:545–554.
- [55] Ashworth S, Rabiner EA, Gunn RN, et al. Evaluation of ¹¹C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. *J Nucl Med* 2010;51:1021–1029.

- [56] Otsuka T, Ito H, Halldin C, et al. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH₃O-N-n-propylnorapomorphine in the human brain. *J Nucl Med* 2009;50:703–710.
- [57] Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. *J Nucl Med* 2009; 50:2–5.
- [58] Ray P, Tsien R, Gambhir SS. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. *Cancer Res* 2007;67:3085–3093.
- [59] Hoffend J, Mier W, Schuhmacher J, et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. *Nucl Med Biol* 2005;32:287–292.
- [60] Qi J, Leahy RM. Resolution and noise properties of MAP reconstruction for fully 3-D PET. *IEEE T Med Imaging* 2000;19:493–506.
- [61] Qi J, Leahy RM, Cherry SR, Chatzioannou A, Farquhar TH. High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. *Phys Med Biol* 1998; 43:1001–1013.
- [62] Al-Nahhas A, Win Z, Szyszko T, et al. Gallium-68 PET: a new frontier in receptor cancer imaging. *Anticancer Res* 2007;27:4087–4094.
- [63] Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. *Chem Rev* 2010;110:2858–2902.
- [64] Haacke EM. *Magnetic resonance imaging : physical principles and sequence design*. New York: J. Wiley & Sons, 1999.
- [65] Deese AJ, Dratz EA, Hymel L, Fleischer S. Proton NMR T₁, T₂, and T₁ rho relaxation studies of native and reconstituted sarcoplasmic reticulum and phospholipid vesicles. *Biophys J* 1982;37:207–216.
- [66] Bernstein MA, King KF, Zhou ZJ. *Handbook of MRI pulse sequences*. Burlington, MA: Elsevier Academic Press, 2004.

- [67] Liang ZP, Lauterbur PC, IEEE Engineering in Medicine and Biology Society. Principles of magnetic resonance imaging a signal processing perspective. Bellingham, Wash. New York: SPIE Optical Engineering Press ; IEEE Press,, 2000.
- [68] Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. *J Chem Phys* 1965;42:288–292.
- [69] Le Bihan D, Breton E. {Imagerie de diffusion in vivo par Résonance Magnétique Nucléaire.}. XXX CR Académie des Sciences de Paris 1985;301:1109–1112.
- [70] Colvin DC, Loveless ME, Does MD, Yue Z, Yankeelov TE, Gore JC. Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients. *Magn Reson Imaging* 2010;.
- [71] Colvin DC, Yankeelov TE, Does MD, Yue Z, Quarles C, Gore JC. New insights into tumor microstructure using temporal diffusion spectroscopy. *Cancer Res* 2008;68:5941–5947.
- [72] Gore JC, Yankeelov TE, Peterson TE, Avison MJ. Molecular imaging without radiopharmaceuticals? *J Nucl Med* 2009;50:999–1007.
- [73] Hagmann P, Jonasson L, Maeder P, Thiran JP, Wedeen VJ, Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. *Radiographics* 2006;26:S205–S223.
- [74] Hoff BA, Chenevert TL, Bhojani MS, et al. Assessment of multiexponential diffusion features as MRI cancer therapy response metrics. *Magnet Reson Med* 2010;64:1499–1509.
- [75] Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. *The Prostate* 2005;62:140–147.
- [76] Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. *J Magn Reson Imaging* 2002;16:407–422.
- [77] Yankeelov TE, Avison MJ, Damon BM, Manning HC, Peterson TE, Gore JC. Frontiers of

- biomedical imaging science 2009: workshop report and research opportunities. *Cancer Res* 2009;69:7902–7904.
- [78] Daldrup-Link HE, Golovko D, Ruffell B, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. *Clin Cancer Res* 2011;17:5695–5704.
- [79] Perles-Barbacaru TA, Procissi D, Demyanenko AV, Hall FS, Uhl GR, Jacobs RE. Quantitative pharmacologic MRI: mapping the cerebral blood volume response to cocaine in dopamine transporter knockout mice. *Neuroimage* 2011;55:622–628.
- [80] Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. *J Magn Reson Imaging* 1997;7:91–101.
- [81] Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. *Magnet Reson Med* 1991; 17:357–367.
- [82] Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. *Curr Med Imaging Rev* 2009; 3:91–107.
- [83] Li X, Huang W, Yankeelov TE, Tudorica A, Rooney WD, Springer Jr CS. Shutter-speed analysis of contrast reagent bolus-tracking data: Preliminary observations in benign and malignant breast disease. *Magnet Reson Med* 2005;53:724–729.
- [84] Yankeelov TE, Cron GO, Addison CL, et al. Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. *Magnet Reson Med* 2007; 57:353–361.
- [85] Yankeelov TE, Luci JJ, DeBusk LM, Lin PC, Gore JC. Incorporating the effects of transcytolemmal water exchange in a reference region model for DCE-MRI analysis: theory, simulations, and experimental results. *Magnet Reson Med* 2008;59:326–335.
- [86] Yankeelov TE, Rooney WD, Huang W, et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. *NMR Biomed* 2005;18:173–185.

- [87] Catana C, van der Kouwe A, Benner T, et al. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. *J Nucl Med* 2010;51:1431–1438.
- [88] Hofmann M, Pichler B, Schölkopf B, Beyer T. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. *Eur J Nucl Med Mol I* 2009;36:93–104.
- [89] Catana C, van der Kouwe A, Benner T, et al. Rigid-body MR-assisted PET motion correction. *J Nucl Med* 2009;50:592.
- [90] Frullano L, Catana C, Benner T, Sherry AD, Caravan P. Bimodal MR-PET agent for quantitative pH imaging. *Angew Chem Int Ed Engl* 2010;49:2382–2384.
- [91] Cho ZH, Son YD, Kim HK, et al. A hybrid PET-MRI: An integrated molecular-genetic imaging system with HRRT-PET and 7.0-T MRI. *Int J Imag Syst Tech* 2007;17:252–265.
- [92] Zaidi H, Ojha N, Morich M, et al. Design and performance evaluation of a whole-body Ingenuity TF PET/MRI system. *Phys Med Biol* 2011;56:3091.
- [93] Bindseil GA, Gilbert KM, Scholl TJ, Handler WB, Chronik BA. First image from a combined positron emission tomography and field-cycled MRI system. *Magnet Reson Med* 2011; 66:301–305.
- [94] Lucas AJ, Hawkes RC, Ansorge RE, et al. Development of a combined microPET-MR system. *Technol Cancer Res Treat* 2006;5:337–341.
- [95] Delso G, Fürst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. *J Nucl Med* 2011;.
- [96] Mackewn JE, Halsted P, Charles-Edwards G, et al. Performance evaluation of an MRI-compatible pre-clinical PET system using long optical fibers. *IEEE T Nucl Sci* 2010; 57:1052–1062.
- [97] Raylman RR, Majewski S, Velan SS, et al. Simultaneous acquisition of magnetic resonance spectroscopy (MRS) data and positron emission tomography (PET) images with a prototype MR-compatible, small animal PET imager. *J Magn Reson* 2007;186:305–310.

- [98] Tatsumi M, Yamamoto S, Imaizumi M, et al. Simultaneous PET/MR body imaging in rats: initial experiences with an integrated PET/MRI scanner. *Ann Nucl Med* 2012;.
- [99] Yiping S, Simon RC, Keyvan F, et al. Simultaneous PET and MR imaging. *Phys Med Biol* 1997;42:1965.
- [100] Catana C, Benner T, van der Kouwe A, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. *J Nucl Med* 2011;52:154–161.
- [101] Maramraju SH, al E, Smith SD, et al. Small animal simultaneous PET/MRI: initial experiences in a 9.4 T microMRI. *Phys Med Biol* 2011;56:2459–2480.
- [102] Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. *Nat Med* 2008;14:459–465.
- [103] Seiichi Y, Tadashi W, Hiroshi W, et al. Simultaneous imaging using Si-PM-based PET and MRI for development of an integrated PET/MRI system. *Phys Med Biol* 2012;57:N1.
- [104] Yoon HS, Ko GB, Kwon SI, et al. Initial results of simultaneous PET/MRI experiments with an MRI-compatible silicon photomultiplier PET scanner. *J Nucl Med* 2012;53:608–614.
- [105] Catana C, Procissi D, Wu Y, et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. *P Natl Acad Sci Usa* 2008;105:3705–3710.
- [106] Catana C. Development of an integrated multi-slice PET-MRI scanner using fiber optically coupled LSO/PSAPD detectors. Ph.D. thesis, University of California, Davis, 2007.
- [107] Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. *Clin Cancer Res* 2007;13:3552–3558.
- [108] Humm JL, Ballon D, Hu YC, et al. A stereotactic method for the three-dimensional registration of multi-modality biologic images in animals: NMR, PET, histology, and autoradiography. *Med Phys* 2003;30:2303–2314.

- [109] Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. *J Nucl Med* 2005;46:675–682.
- [110] Johnston RF, Pickett SC, Barker DL. Autoradiography using storage phosphor technology. *Electrophoresis* 1990;11:355–360.
- [111] Yaghoubi SS, Berger F, Gambhir SS. Studying the biodistribution of positron emission tomography reporter probes in mice. *Nat Protocols* 2007;2:1752–1755.
- [112] Christian N, Lee JA, Bol A, De Bast M, Gallez B, Gregoire V. Immobilization device for in vivo and in vitro multimodality image registration of rodent tumors. *Radiother Oncol* 2008;87:147–151.
- [113] Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. *Clin Cancer Res* 2008;14:2171–2179.
- [114] Loomis K, McNeeley K, Bellamkonda RV. Nanoparticles with targeting, triggered release, and imaging functionality for cancer applications. *Soft Matter* 2011;7:839–856.
- [115] Bading J, Ng T, Jacobs R, Raubitschek A, Colcher D. [Cu-64]-DOTA-Herceptin: radiosynthesis and initial evaluation in vivo. *J Nucl Med* 2009;50:1912–.
- [116] Li L, Bading J, Yazaki PJ, et al. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. *Bioconjugate Chem* 2008;19:89–96.
- [117] Wong JYC, Raubitschek A, Yamauchi D, et al. A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. *Cancer Biol Ther* 2010;25:387–394.
- [118] Wu Y, Ng TSC, Yang Y, Shah K, Farrell R, Cherry SR. A study of the timing properties of position-sensitive avalanche photodiodes. *Phys Med Biol* 2009;54:5155.

- [119] Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. *Adv Drug Deliv Rev* 2008;60:1252–1265.
- [120] Artemov D, Mori N, Ravi R, Bhujwala ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. *Cancer Res* 2003;63:2723–2727.
- [121] Rapoport N, Nam KH, Gupta R, et al. Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. *J Control Release* 2011;153:4–15.
- [122] Fidarova EF, El-Emir E, Boxer GM, et al. Microdistribution of targeted, fluorescently labeled anti-Carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. *Clin Cancer Res* 2008;14:2639–2646.
- [123] Kobayashi H, Shirakawa K, Kawamoto S, et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)₂₅₆. *Cancer Res* 2002;62:860–866.
- [124] Thurber GM, Weissleder R. A systems approach for tumor pharmacokinetics. *PLoS ONE* 2011;6:e24696.
- [125] Lippens RJ. Liposomal daunorubicin (daunoxome) in children with recurrent or progressive brain tumors. *Pediatr Hemat Oncol* 1999;16:131–139.
- [126] Valle JW, Armstrong A, Newman C, et al. A phase 2 study of sp1049c, doxorubicin in p-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. *Invest New Drug* 2011;29:1029–1037.
- [127] Amadori D, Milandri C, Comella G, et al. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. *European journal of cancer (Oxford, England : 1990)* 2011;47:2091–2098.

- [128] Kobrinsky B, Andreopoulou E, Mourtzikos K, Muggia F. Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal Doxorubicin. *Clin Med Oncol* 2008;2:469–470.
- [129] Link J, Waisman J, Nguyen B, Jacobs C. Bevacizumab and Albumin-Bound Paclitaxel Treatment in Metastatic Breast Cancer. *Clin Breast Cancer* 2007;7:779–783.
- [130] Hamstra DA, Galbán CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. *J Clin Oncol* 2008;26:3387–3394.
- [131] Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. *J Magn Reson Imaging* 2002;16:407–422.
- [132] Ellingson BM, LaViolette PS, Rand SD, et al. Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. *Magnet Reson Med* 2011;65:1131–1143.
- [133] Yankeelov TE, Atuegwu NC, Deane NG, Gore JC. Modeling tumor growth and treatment response based on quantitative imaging data. *Integr Biol (Camb)* 2010;2:338–345.
- [134] Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. *Lancet Oncol* 2010;11:1172–1183.
- [135] Zhang F, Zhu L, Liu G, et al. Multimodality imaging of tumor response to doxil. *Theranostics* 2011;1:302–309.
- [136] Sun X, Yan Y, Liu S, et al. ¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of response to abraxane therapy. *J Nucl Med* 2011;52:140–146.
- [137] Weber H, Paul D, Elverfeldt DV, Hennig J, Zaitsev M. Extended multi-flip-angle B1 mapping: A 3D mapping method for inhomogeneous B1 fields. *Concept Magn Reson B* 2010;37B:203–214.
- [138] Wehrl HF, Judenhofer MS, Thielscher A, Martirosian P, Schick F, Pichler BJ. Assessment

of MR compatibility of a PET insert developed for simultaneous multiparametric PET/MR imaging on an animal system operating at 7 T. *Magnet Reson Med* 2011;65:269–279.

- [139] Cheng HLM, Wright GA. Rapid high-resolution T1 mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. *Magnet Reson Med* 2006;55:566–574.
- [140] Metzger GJ, Snyder C, Akgun C, Vaughan T, Ugurbil K, Van de Moortele PF. Local B1+ shimming for prostate imaging with transceiver arrays at 7T based on subject-dependent transmit phase measurements. *Magnet Reson Med* 2008;59:396–409.
- [141] Vaughan JT, Garwood M, Collins CM, et al. 7T vs. 4T: RF power, homogeneity, and signal-to-noise comparison in head images. *Magnet Reson Med* 2001;46:24–30.
- [142] Peng B. Studies of the Interactions of the MRI System with the PET insert in the Bore of a 7T Magnet and its Applications. Ph.D. thesis, University of California, Davis, 2010.
- [143] Doubrovin M, Serganova I, Mayer-Kuckuk P, Ponomarev V, Blasberg RG. Multimodality in vivo molecular-genetic imaging. *Bioconjugate Chem* 2004;15:1376–1388.
- [144] Ottobriani L, Ciana P, Biserni A, Lucignani G, Maggi A. Molecular imaging: a new way to study molecular processes in vivo. *Mol Cell Endocrinol* 2006;246:69–75.
- [145] Rehemtulla A, Hall DE, Stegman LD, et al. Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. *P Soc Photo-Opt Ins* 2002; 1:43–55.
- [146] Stell A, Belcredito S, Ramachandran B, et al. Multimodality imaging: novel pharmacological applications of reporter systems. *Q J Nucl Med Mol Im* 2007;51:127–138.
- [147] Deroose CM, De A, Loening AM, et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. *J Nucl Med* 2007;48:295–303.
- [148] la Fougere C, Hundt W, Brockel N, et al. Value of PET/CT versus PET and CT performed

- as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. *Eur J Nucl Med Mol I* 2006;33:1417–1425.
- [149] Pichler BJ, Judenhofer MS, Pfannenbergl C. Multimodal imaging approaches: PET/CT and PET/MRI. *Handb Exp Pharmacol* 2008;109–132.
- [150] Roldan-Valadez E, Ortega-Lopez N, Cervera-Ceballos E, Valdivieso-Cardenas G, Vega-Gonzalez I, Granados-Garcia M. Whole-body (18)F-FDG PET/CT in primary non-Hodgkin's lymphoma of the thyroid associated with Hashimoto's thyroiditis and bilateral kidney infiltration. *Rev Esp Med Nucl* 2008;27:34–39.
- [151] Jan ML, Ni YC, Chen KW, Liang HC, Chuang KS, Fu YK. A combined micro-PET/CT scanner for small animal imaging. *Nucl Instrum Meth A* 2006;569:314–318.
- [152] Slomka PJ, Baum RP. Multimodality image registration with software: state-of-the-art. *Eur J Nucl Med Mol I* 2008;.
- [153] Chow PL, Stout DB, Komisopoulou E, Chatziioannou AF. A method of image registration for small animal, multi-modality imaging. *Phys Med Biol* 2006;379.
- [154] Rodriguez-Ruano A, Pascau J, Chamorro J, et al. PET/CT alignment for small animal scanners based on capillary detection. In: *Nuclear Science Symposium Conference Record, 2008. NSS '08. IEEE*. 2008 3832–3835.
- [155] Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. *P Natl Acad Sci Usa* 1990;87:9868–9872.
- [156] Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology. *J Clin Oncol* 2007;25:4104–4109.
- [157] Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. *Annu Rev Biomed Eng* 2005;7:287–326.
- [158] Jacobs RE, Cherry SR. Complementary emerging techniques: high-resolution PET and MRI. *Curr Opin Neurobiol* 2001;11:621–629.

- [159] Bindseil G, Handler W, Scholl T, Gilbert K, Peng H, Chronik B. Design of a combined PET and field-cycled MRI system for small animal imaging. In: Proceedings 16th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Toronto, 2008 351.
- [160] Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Cherry SR. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. *J Nucl Med* 2006;47:1968–1976.
- [161] Zhang Z, Ramirez NE, Yankeelov TE, et al. $\alpha_2\beta_1$ integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. *Blood* 2008; 111:1980–1988.
- [162] Judenhofer MS, Pichler BJ, Cherry SR. Evaluation of high performance data acquisition boards for simultaneous sampling of fast signals from PET detectors. *Phys Med Biol* 2005; 50:29–44.
- [163] Goshtasby A. Image registration by local approximation methods. *Image Vision Comput* 1988;6:255–261.
- [164] Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. *Cancer Lett* 2006;242:1–10.
- [165] Zhang M, Huang M, Le C, et al. Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies. *Phys Med Biol* 2008;53:5867–5882.
- [166] Pfluger T, Vollmar C, Wismuller A, et al. Quantitative comparison of automatic and interactive methods for MRI-SPECT image registration of the brain based on 3-dimensional calculation of error. *J Nucl Med* 2000;41:1823–1829.
- [167] Jupp B, O'Brien TJ. Application of coregistration for imaging of animal models of epilepsy. *Epilepsia* 2007;48 Suppl 4:82–89.
- [168] Rowland DJ, Garbow JR, Laforest R, Snyder AZ. Registration of [18F]FDG microPET and small-animal MRI. *Nucl Med Biol* 2005;32:567–572.

- [169] Slomka PJ. Software approach to merging molecular with anatomic information. *J Nucl Med* 2004;45 Suppl 1:36S–45S.
- [170] Twieg DB. The k-trajectory formulation of the NMR imaging process with applications in analysis and synthesis of imaging methods. *Med Phys* 1983;10:610–621.
- [171] Bowtell R, Mansfield P. Gradient coil design using active magnetic screening. *Magnet Reson Med* 1991;17:15–21.
- [172] Barmet C, De Zanche N, Wilm BJ, Pruessmann KP. A transmit/receive system for magnetic field monitoring of in vivo MRI. *Magnet Reson Med* 2009;62:269–276.
- [173] Barmet C, Zanche ND, Pruessmann KP. Spatiotemporal magnetic field monitoring for MR. *Magnet Reson Med* 2008;60:187–197.
- [174] Papadakis NG, Smponias T, Berwick J, Mayhew JEW. k-space correction of eddy-current-induced distortions in diffusion-weighted echo-planar imaging. *Magnet Reson Med* 2005; 53:1103–1111.
- [175] Blümer P. Spatially resolved magnetic resonance : methods, materials, medicine, biology, rheology, geology, ecology, hardware. Weinheim ; New York: Wiley-VCH, 1998.
- [176] Montagner J, Barra V, Boire JY. A geometrical approach to multiresolution management in the fusion of digital images. In: *Pixelization Paradigm*. 2008 121–136.
- [177] Reveillès JP. The geometry of the intersection of voxel spaces. *Electron Notes Theor Comput Sci* 2001;46:285–308.
- [178] Agrawal G, Chen JH, Baek HM, et al. MRI features of breast cancer: a correlation study with HER-2 receptor. *Ann Oncol* 2007;18:1903–1904.
- [179] Brindle K. New approaches for imaging tumour responses to treatment. *Nat Rev Cancer* 2008;8:94–107.
- [180] Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer* 2004;4:891–899.

- [181] Guo J, Higashi K, Yokota H, et al. In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma. *J Nucl Med* 2004;45:1334–1339.
- [182] Zhou R, Pickup S, Yankeelov TE, Springer Jr CS, Glickson JD. Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange. *Magnet Reson Med* 2004;52:248–257.
- [183] Cho H, Ackerstaff E, Carlin S, et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. *Neoplasia* 2009;11:247–259.
- [184] Gee MS, Upadhyay R, Bergquist H, et al. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. *Radiology* 2008;248:925–935.
- [185] Serganova I, Blasberg R. Reporter gene imaging: potential impact on therapy. *Nucl Med Biol* 2005;32:763–780.
- [186] Jarrett BR, Gustafsson B, Kukis DL, Louie AY. Synthesis of ⁶⁴Cu-labeled magnetic nanoparticles for multimodal imaging. *Bioconjugate Chem* 2008;19:1496–1504.
- [187] Thayer D, Unlu MB, Lin Y, Yan K, Nalcioglu O, Gulsen G. Dual-contrast dynamic MRI-DOT for small animal imaging. *Technol Cancer Res Treat* 2010;9:61–70.
- [188] Horn BKP. Closed-form solution of absolute orientation using unit quaternions. *J Opt Soc Am A* 1987;4:629–642.
- [189] Bebis G, Boyle R, Koracin D, et al. *Advances in Visual Computing* (vol. # 4292) Second International Symposium, ISVC 2006, Lake Tahoe, NV, USA, November 6-8, 2006, Proceedings, Part II, 2006.
- [190] Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. *Trends Mol Med* 2010;16:508–515.

- [191] Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. *J Magn Reson Imaging* 2003;17:509–520.
- [192] Galbán CJ, Bhojani MS, Lee KC, et al. Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. *Clin Cancer Res* 2010;16:1542–1552.
- [193] Li X, Yankeelov TE, Peterson TE, Gore JC, Dawant BM. Automatic nonrigid registration of whole body CT mice images. *Med Phys* 2008;35:1507–1520.
- [194] Yang Y, Tai YC, Siegel S, et al. Optimization and performance evaluation of the microPET II scanner for in vivo small-animal imaging. *Phys Med Biol* 2004;49:2527–2545.
- [195] Metz S, Ganter C, Lorenzen S, et al. Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alpha-v-beta3 expression, and glucose metabolism. *J Nucl Med* 2010;51:1691–1698.
- [196] NEMA. Performance measurements of small-animal positron emission tomographs. Tech. rep., National Electrical Manufacturers Association., Rosslyn, VA, 2008.
- [197] Coe RA. Quantitative whole-body autoradiography. *Regul Toxicol Pharm* 2000;31:S1–3.
- [198] Wu Y, Catana C, Farrell R, et al. PET performance evaluation of an MR-Compatible PET insert. *IEEE T Nucl Sci* 2009;56:574–580.
- [199] Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human Carcinoembryonic antigen as a model for immunotherapy. *Cancer Res* 1998;58:1469–1477.
- [200] Knoess C, al E, Siegel S, et al. Performance evaluation of the microPET R4 PET scanner for rodents. *Eur J Nucl Med Mol I* 2003;30:737.
- [201] Ng TSC, Procissi D, Wu Y, Jacobs RE. A robust coregistration method for in vivo studies using a first generation simultaneous PET/MR scanner. *Med Phys* 2010;37:1995–2003.
- [202] Zhou W, Bovik AC, Sheikh HR, Simoncelli EP. Image quality assessment: from error visibility to structural similarity. *IEEE T Med Imaging* 2004;13:600–612.

- [203] Sampat MP, Zhou W, Gupta S, Bovik AC, Markey MK. Complex Wavelet Structural Similarity: A New Image Similarity Index. *IEEE T Image Process* 2009;18:2385–2401.
- [204] Disselhorst JA, Brom M, Laverman P, et al. Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small-Animal PET Scanner. *J Nucl Med* 2010;51:610–617.
- [205] Laforest R, Longford D, Siegel S, Newport DF, Yap J. Performance Evaluation of the microPET-FOCUS-F120. *Nuclear Science, IEEE Transactions on* 2007;54:42–49.
- [206] Christian N, Lee JA, Bol A, De Bast M, Jordan B, Grégoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. *Radiother Oncol* 2009;91:101–106.
- [207] Chow PL, Rannou FR, Chatziioannou AF. Attenuation correction for small animal PET tomographs. *Phys Med Biol* 2005;50:1837–1850.
- [208] Atuegwu NC, Gore JC, Yankeelov TE. The integration of quantitative multi-modality imaging data into mathematical models of tumors. *Phys Med Biol* 2010;55:2429–2449.
- [209] York D, Evensen NM, Martinez ML, Delgado JD. Unified equations for the slope, intercept, and standard errors of the best straight line. *Am J Phys* 2004;72:367–375.
- [210] Christian N, Lee JA, Bol A, De Bast M, Gallez B, Grégoire V. Immobilization device for in vivo and in vitro multimodality image registration of rodent tumors. *Radiother Oncol* 2008; 87:147–151.
- [211] Weirich C, Brenner D, Tellmann L, Herzog H, Shah N. Systematic investigation and correction of MR influences on simultaneous PET measurements. In: *Proceedings 19th Scientific Meeting, International Society for Magnetic Resonance in Medicine*. 2011 3796.
- [212] Vandenbroucke A, Lee J, Spanoudaki V, Lau F, Reynolds PD, Levin CS. Temperature and bias voltage studies of a large area position sensitive Avalanche Photodiode. In: *Nuclear Science Symposium Conference Record (NSS/MIC), 2009 IEEE*. 2009 3664–3669.
- [213] Wu Y, Yang Y, Bec J, Cherry SR. A DOI-capable MR-compatible PET insert for simultaneous PET/MRI imaging. *Mol Imaging Biol* 2010;12:S603.

- [214] Cho K, Wang X, Nie S, Chen Z, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. *Clin Cancer Res* 2008;14:1310–1316.
- [215] Gribben JG. How I treat indolent lymphoma. *Blood* 2007;109:4617–4626.
- [216] Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. *Hematology* 2009;2009:497–506.
- [217] Numbenjapon T, Wang J, Colcher D, et al. Preclinical results of Camptothecin-polymer conjugate (IT-101) in multiple human Lymphoma xenograft models. *Clin Cancer Res* 2009;15:4365–4373.
- [218] Armitage JO. Early-stage Hodgkin's Lymphoma. *New Engl J Med* 2010;363:653–662.
- [219] Yen Y, Coerver LA, Garmey EG, et al. Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies. *Mol Cancer Ther* 2011;10:Supplement 1.
- [220] Zhao B, Schwartz LH, Larson SM. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. *J Nucl Med* 2009;50:239–249.
- [221] Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. *Crit Rev Oncol Hemat* 2009;72:217–238.
- [222] Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI—a potential new biomarker of response to cancer therapy. *Nat Clin Pract Oncol* 2008;5:220–233.
- [223] Huang MQ, Pickup S, Nelson DS, et al. Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T2-weighted and diffusion-weighted MRI. *NMR Biomed* 2008;21:1021–1029.
- [224] Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. *Clin Cancer Res* 2007;13:443–450.

- [225] Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. *Clin Cancer Res* 2009;15:986–994.
- [226] Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. *P Natl Acad Sci Usa* 2005;102:16759–16764.
- [227] Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. *Clin Cancer Res* 2008;14:3832–3839.
- [228] Deisboeck TS, Wang Z, Macklin P, Cristini V. Multiscale cancer modeling. *Annu Rev Biomed Eng* 2011;13:127–155.
- [229] Yankeelov TE, Atuegwu NC, Deane NG, Gore JC. Modeling tumor growth and treatment response based on quantitative imaging data. *Integr Biol (Camb)* 2010;2:338–345.
- [230] Atuegwu NC, Colvin DC, Loveless ME, Xu L, Gore JC, Yankeelov TE. Incorporation of diffusion-weighted magnetic resonance imaging data into a simple mathematical model of tumor growth. *Phys Med Biol* 2012;57:225.
- [231] Rockne R, Rockhill JK, Mrugala M, et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. *Phys Med Biol* 2010; 55:3271.
- [232] Wang CH, Rockhill JK, Mrugala M, et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. *Cancer Res* 2009;69:9133–9140.
- [233] Xinjian C, Summers R, Jianhua Y. FEM-Based 3-D tumor growth prediction for kidney tumor. *IEEE T Biomed Eng* 2011;58:463–467.
- [234] Swanson KR, Rockne RC, Claridge J, Chaplain MAJ, Alvord EC, Anderson ARA. Quantifying the role of angiogenesis in malignant progression of gliomas: In silico modeling integrates imaging and histology. *Cancer Res* 2011;.

- [235] Brown CE, Wright CL, Naranjo A, et al. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. *J Immunol Methods* 2005;297:39–52.
- [236] Thomas DL, Lythgoe MF, Pell GS, Calamante F, Ordidge RJ. The measurement of diffusion and perfusion in biological systems using magnetic resonance imaging. *Phys Med Biol* 2000;45:R97–138.
- [237] Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. *Blood* 2006;107:52–59.
- [238] Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. *Ann Oncol* 2005;16:1514–1523.
- [239] Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C. 18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. *J Nucl Med* 2009;50:1102–1109.
- [240] Graf N, Herrmann K, den Hollander J, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. *Mol Imaging Biol* 2008;10:349–355.
- [241] van Waarde A, Cobben DCP, Suurmeijer AJH, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from Inflammation in a rodent model. *J Nucl Med* 2004;45:695–700.
- [242] Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. *New Engl J Med* 2009;361:849–857.
- [243] Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppe H. Neuropilin-1 expression in cancer and development. *J Pathol* 2012;226:50–60.
- [244] Pan Q, Chantry Y, Liang WC, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. *Cancer Cell* 2007;11:53–67.
- [245] Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer. *J Nucl Med* 2009;50:1168–1177.

- [246] Bernatchez PN, Rollin S, Soker S, Sirois MG. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. *Journal of Cellular Biochemistry* 2002;85:629–639.
- [247] Gray MJ, Wey JS, Belcheva A, et al. Neuropilin-1 Suppresses Tumorigenic Properties in a Human Pancreatic Adenocarcinoma Cell Line Lacking Neuropilin-1 Coreceptors. *Cancer Research* 2005;65:3664–3670.
- [248] Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. *Princess Takamatsu Symp* 1991;22:339–347.
- [249] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1995; 1:27–30.
- [250] Huang W, Li X, Morris EA, et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. *P Natl Acad Sci Usa* 2008; 105:17943–17948.
- [251] Hylton N. Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker. *J Clin Oncol* 2006;24:3293–3298.
- [252] Radjenovic A, Dall BJ, Ridgway JP, Smith MA. Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. *Brit J Radiol* 2008;81:120–128.
- [253] Matsumoto S, Yasui H, Batra S, et al. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. *P Natl Acad Sci Usa* 2009; 106:17898–17903.
- [254] Folkman J. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* 2002;29:15–18.
- [255] Ah-See MLW, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. *Clin Cancer Res* 2008;14:6580–6589.

- [256] Hirashima Y, Yamada Y, Tateishi U, et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. *Int J Cancer* 2011;.
- [257] Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer. *J Clin Oncol* 2006; 24:769–777.
- [258] Su MY, Wang Z, Roth GM, Lao X, Samoszuk MK, Nalcioglu O. Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI. *Magnet Reson Med* 1996;36:868–877.
- [259] Wang Z, Su MY, Najafi A, Nalcioglu O. Effect of vasodilator hydralazine on tumor microvascular random flow and blood volume as measured by intravoxel incoherent motion (IVIM) weighted MRI in conjunction with Gd-DTPA-Albumin enhanced MRI. *Magn Reson Imaging* 2001;19:1063–1072.
- [260] Dafni H, Landsman L, Schechter B, Kohen F, Neeman M. MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor. *NMR Biomed* 2002;15:120–131.
- [261] Dafni H, Israely T, Bhujwala ZM, Benjamin LE, Neeman M. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. *Cancer Res* 2002;62:6731–6739.
- [262] Cartwright L, Farhat WA, Sherman C, et al. Dynamic contrast-enhanced MRI to quantify VEGF-enhanced tissue-engineered bladder graft neovascularization: Pilot study. *J Biomed Mater Res A* 2006;77A:390–395.
- [263] Loveless ME, Halliday J, Liess C, et al. A quantitative comparison of the influence of individual versus population-derived vascular input functions on dynamic contrast enhanced-MRI in small animals. *Magnet Reson Med* 2012;67:226–236.

- [264] McGrath DM, Bradley DP, Tessier JL, Lacey T, Taylor CJ, Parker GJM. Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. *Magnet Reson Med* 2009;61:1173–1184.
- [265] Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *New Engl J Med* 2012;366:883–892.
- [266] Marusyk A, Polyak K. Tumor heterogeneity: Causes and consequences. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* 2010;1805:105–117.
- [267] Sirois MG, Edelman ER. VEGF effect on vascular permeability is mediated by synthesis of platelet-activating factor. *Am J Physiol* 1997;272:H2746–56.
- [268] Kim KI, Park JJ, Lee YJ, et al. Gamma camera and optical imaging with a fusion reporter gene using human sodium/iodide symporter and monomeric red fluorescent protein in mouse model. *Int J Radiat Biol* 2011;87:1182–1188.
- [269] Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J. Effect of endotoxin and platelet-activating factor on rat vascular permeability: role of vasoactive mediators. *J Lipid Mediat Cell* 1997;17:31–45.
- [270] Chen Q, Krol A, Wright A, Needham D, Dewhirst MW, Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. *Int J Hyperther* 2008;24:475–482.
- [271] Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. *Circulation* 1998;97:99–107.
- [272] Brkovic A, Sirois MG. Vascular permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis. *Journal of Cellular Biochemistry* 2007;100:727–737.
- [273] Hudry-Clergeon H, Stengel D, Ninio E, Vilgrain I. Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3'-kinase. *The FASEB Journal* 2005;19:512–520.

- [274] Grandclement C, Borg C. Neuropilins: A New Target for Cancer Therapy. *Cancers* 2011; 3:1899–1928.
- [275] Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. *The FASEB Journal* 2000;14:2532–2539.
- [276] Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. *Blood* 2008; 111:2674–2680.
- [277] Becker PM, Waltenberger J, Yachechko R, et al. Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. *Circ Res* 2005;96:1257–1265.
- [278] Hu G, Schwartz DE, Shajahan AN, et al. Isoflurane, but not sevoflurane, increases transendothelial albumin permeability in the isolated rat lung: role for enhanced phosphorylation of caveolin-1. *Anesthesiology* 2006;104:777–785.
- [279] Zhu W, Kato Y, Artemov D. Effect of anesthesia on tumor vascular permeability measurements by DCE-MRI. In: *Proceedings 19th Scientific Meeting, International Society for Magnetic Resonance in Medicine*. 2011 3109.
- [280] Yankeelov TE, DeBusk LM, Billheimer DD, et al. Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. *J Magn Reson Imaging* 2006;24:1140–1147.
- [281] Lin MI, Yu J, Murata T, Sessa WC. Caveolin-1 deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. *Cancer Res* 2007;67:2849–2856.
- [282] Cyran C, Sennino B, Chaopathomkul B, et al. Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. *Eur Radiol* 2009;19:121–131.
- [283] Strijkers GJ, Hak S, Kok MB, Springer CS, Nicolay K. Three-compartment T1 relaxation model for intracellular paramagnetic contrast agents. *Magnet Reson Med* 2009;61:1049–1058.

- [284] Brisset JC, Desestret V, Marcellino S, et al. Quantitative effects of cell internalization of two types of ultrasmall superparamagnetic iron oxide nanoparticles at 4.7 T and 7 T. *Eur Radiol* ;20:275–285.
- [285] Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. *J Clin Invest* 2000;106:829–838.
- [286] Lee TH, Seng S, Sekine M, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. *Plos Med* 2007;4:e186.
- [287] Liu Z, Yan Y, Liu S, Wang F, Chen X. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. *Bioconjugate Chem* 2009;20:1016–1025.
- [288] Bencherif B, Stumpf MJ, Links JM, Frost JJ. Application of MRI-based partial-volume correction to the analysis of PET images of μ -opioid receptors using statistical parametric mapping. *J Nucl Med* 2004;45:402–408.
- [289] Wang H, Fei B. An MR image-guided, voxel-based partial volume correction method for PET images. *Med Phys* 2012;39:179–195.
- [290] Ng T, Procissi D, Wu Y, Jacobs RE. MRI derived arterial input function for radionuclides using combined and simultaneous PET-MRI insert. *Mol Imaging Biol* 2010;12:S229–S230.
- [291] Knoess C, al E. Performance evaluation of the microPET R4 PET scanner for rodents. *Eur J Nucl Med Mol Imaging* 2003;30:737.
- [292] Shimazaki H, Shinomoto S. A method for selecting the bin size of a time histogram. *Neural Comput* 2007;19:1503–1527.
- [293] Valckx FMJ, Thijssen JM. Characterization of echographic image texture by cooccurrence matrix parameters. *Ultrasound in Medicine & Biology* 1997;23:559–571.
- [294] Bankman IN. *Handbook of medical imaging : processing and analysis*. San Diego: Academic, 2000.

- [295] Handrick S, Naimipour B, Raicu D, Furst J. Evaluation of binning strategies for tissue classification in computed tomography images. vol. 6144. San Diego, CA, USA: SPIE, 2006 61444L–11.
- [296] Kim N, Seo JB, Sung YS, et al. Effect of various binning methods and ROI sizes on the accuracy of the automatic classification system for differentiation between diffuse infiltrative lung diseases on the basis of texture features at HRCT. vol. 6914. San Diego, CA, USA: SPIE, 2008 69143N–7.
- [297] Asselin MC, O'Connor JPB, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. *Eur J Cancer* 2012;48:447–455.
- [298] Chen W, Giger ML, Li H, Bick U, Newstead GM. Volumetric texture analysis of breast lesions on contrast-enhanced magnetic resonance images. *Magnet Reson Med* 2007;58:562–571.
- [299] Risse F, Pesic J, Young S, Olsson LE. A texture analysis approach to quantify ventilation changes in hyperpolarised ^3He MRI of the rat lung in an asthma model. *NMR Biomed* 2012; 25:131–141.